 In March, Kite Pharma has announced that it would be collaborating with Genentech, in order to evaluate the safety and efficacy of two of its novel therapies.The target population for the tests would be patients suffering from non-Hodgkin Lymphoma.The therapies in question, KTE-C19 and atezolizumab, would be tested in combination with each other.